Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICRAININ vs PHRENILIN FORTE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
MICRAININ is a combination of acetaminophen (paracetamol) and butalbital. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis and modulating pain perception via activation of descending serotonergic pathways. Butalbital is a barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and causing central nervous system depression.
Butalbital: barbiturate that enhances GABA-A receptor activity, causing CNS depression. Acetaminophen: analgesic and antipyretic via COX inhibition and central action. Caffeine: adenosine receptor antagonist, CNS stimulant.
Tension headache,Migraine (off-label),Muscle contraction headache
Tension-type headache
2 tablets orally at onset of migraine, then 1 tablet every 1-2 hours as needed, up to 4 tablets per attack, not to exceed 6 tablets per day. Each tablet contains isometheptene mucate 65 mg, dichloralphenazone 100 mg, and acetaminophen 325 mg.
1 capsule (butalbital 50 mg, acetaminophen 325 mg, caffeine 40 mg) orally every 4 hours as needed; maximum 6 capsules per day.
Terminal elimination half-life 8-12 hours; in elderly or severe renal impairment, may extend to 24 hours
Butalbital: 35-50 hours (long-acting barbiturate). Acetaminophen: 2-3 hours (therapeutic doses); prolonged in overdose. Caffeine: 3-7 hours (average 5 hours); prolonged in liver disease.
Acetaminophen is primarily metabolized in the liver via glucuronidation and sulfation; a minor pathway via CYP2E1 and CYP3A4 produces the toxic metabolite NAPQI. Butalbital is extensively metabolized by CYP2C19 and other hepatic enzymes.
Butalbital: primarily hepatic via CYP2C19 and CYP2C9. Acetaminophen: hepatic via glucuronidation (UGT1A1, UGT1A9, UGT2B15), sulfation, and CYP2E1 (minor). Caffeine: hepatic via CYP1A2.
Primarily renal (70% unchanged, 20% as sulfate conjugate); biliary/fecal <10%
Butalbital: ~60-70% renal as unchanged drug and metabolites. Acetaminophen: ~85% renal as sulfate and glucuronide conjugates (2-4% unchanged). Caffeine: ~1% renal unchanged; major metabolites are paraxanthine, theobromine, and theophylline eliminated renally.
70-80% bound to albumin
Butalbital: ~30% bound to plasma proteins. Acetaminophen: <5% bound at therapeutic levels. Caffeine: ~35% bound to albumin.
0.3-0.5 L/kg; indicates moderate distribution into total body water
Butalbital: ~0.8 L/kg (widely distributed). Acetaminophen: ~1 L/kg. Caffeine: ~0.6 L/kg.
Oral: 60-70% (due to first-pass metabolism); Intramuscular: 75-85%; Intravenous: 100%
Oral bioavailability: Butalbital 90% (well absorbed); Acetaminophen 85-95%; Caffeine 99% (essentially complete).
Not studied; use caution with Cr Cl <30 m L/min. Avoid if severe renal impairment (Cr Cl <15 m L/min) due to acetaminophen and dichloralphenazone accumulation. No specific dose adjustment guidelines available.
Not formally established. Acetaminophen component: avoid in severe renal impairment (Cr Cl <10 m L/min) due to accumulation of metabolites; adjust dosing interval to every 6 hours for Cr Cl 10-50 m L/min.
Contraindicated in severe hepatic impairment (Child-Pugh C). In moderate impairment (Child-Pugh B), reduce dose by 50% or increase dosing interval. In mild impairment (Child-Pugh A), no adjustment necessary but monitor.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B): reduce dose to 1 capsule every 6 hours and monitor for hepatotoxicity.
Not recommended for pediatric patients due to lack of safety and efficacy data; alternative agents preferred.
Not recommended for pediatric patients due to risk of butalbital dependence and acetaminophen hepatotoxicity. Alternative agents preferred.
Use with caution due to increased sensitivity to anticholinergic effects, sedation, and hepatotoxicity. Initiate at lower doses (e.g., 1 tablet at onset) and titrate slowly. Monitor renal and hepatic function.
Initiate at 1 capsule every 6 hours; maximum 4 capsules daily. Renal and hepatic function should be monitored, and dose adjusted accordingly.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
Acetaminophen may cause severe hepatic injury, including acute liver failure, sometimes resulting in liver transplant or death. Butalbital is habit forming and may be abused; limit use to intermittent treatment.
Hepatotoxicity: Severe liver injury may occur with acetaminophen, especially with chronic use or doses >4000 mg/day. Monitor liver function. Dependence: Butalbital can cause tolerance and dependence; withdrawal symptoms may occur upon abrupt discontinuation. CNS depression: May impair mental and physical abilities; caution with alcohol or other CNS depressants. Renal impairment: Use with caution in patients with severe renal disease.
Hepatotoxicity with acetaminophen overdose; avoid exceeding 4 g/day. Risk of dependence, abuse, and withdrawal with butalbital. CNS depression; avoid alcohol and other sedatives. Renal impairment, hepatic impairment.
Hypersensitivity to acetaminophen, butalbital, or any component; porphyria; severe hepatic impairment; history of barbiturate dependence.
Hypersensitivity to any component; porphyria; severe hepatic impairment; concomitant MAO inhibitor use (or within 14 days)
Avoid excessive caffeine intake from coffee, tea, soda, or chocolate as it may increase caffeine-related side effects. Grapefruit juice may potentiate effects; limit consumption. Alcohol increases risk of drowsiness and hepatotoxicity.
Avoid alcohol and caffeine-containing foods/drinks (e.g., coffee, tea, cola, chocolate) as they may increase side effects like jitteriness or insomnia. Grapefruit juice may alter caffeine metabolism; consider avoiding. No significant food interactions with acetaminophen or butalbital.
MICRAININ is a combination of butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate; barbiturates are associated with increased risk of congenital malformations, particularly neural tube defects, when used in the first trimester. Chronic use in the third trimester can lead to neonatal withdrawal syndrome and floppy infant syndrome. Acetaminophen is generally considered low risk at therapeutic doses. Caffeine in moderate amounts is not strongly associated with major malformations, but high doses may increase risk of miscarriage.
First trimester: Butalbital (barbiturate) associated with oral clefts, neural tube defects; acetaminophen generally safe, but high doses may cause oxidative stress. Second/third trimester: Butalbital may cause fetal dependence and withdrawal; acetaminophen safe at therapeutic doses. Avoid in pregnancy unless benefit outweighs risk.
Butalbital is excreted into breast milk; the milk-to-plasma ratio is approximately 0.3-0.6. Infants are at risk of sedation, poor feeding, and withdrawal. Acetaminophen is excreted in low amounts (M/P ~0.2-0.9) and is considered compatible. Caffeine is excreted in breast milk (M/P ~0.5) and may cause irritability in infants. Use of MICRAININ during breastfeeding is generally not recommended due to butalbital.
Acetaminophen: minimal excretion, M/P ratio ~0.9, considered compatible. Butalbital: excreted in breast milk, M/P ratio ~0.6, may cause infant drowsiness or withdrawal; caution advised. Caffeine: M/P ratio ~0.5-0.8, generally safe in moderate amounts.
No specific pharmacokinetic data for MICRAININ during pregnancy. Pregnancy can alter metabolism of acetaminophen and caffeine. Butalbital clearance may increase due to enhanced hepatic metabolism. However, dose adjustments are not typically recommended. Use the lowest effective dose for the shortest duration.
Increased renal clearance and volume of distribution in pregnancy may reduce acetaminophen and caffeine levels; no standard dose adjustment recommended. Butalbital: increased clearance due to hepatic enzyme induction and increased Vd; monitor for reduced efficacy; adjust dose based on clinical response. Avoid supratherapeutic doses.
MICRAININ is a fixed-dose combination of butalbital, acetaminophen, and caffeine, used for tension-type headache. Butalbital is a barbiturate with abuse potential; limit quantity prescribed. Acetaminophen hepatotoxicity risk with >3000 mg/day. Caffeine may exacerbate anxiety or insomnia. Avoid in porphyria, severe hepatic impairment, or history of substance abuse. Contraindicated with MAOIs.
Phrenilin Forte is a combination of butalbital, acetaminophen, and caffeine used for tension-type headaches. Butalbital is a barbiturate with high abuse potential; limit to short-term use. Acetaminophen hepatotoxicity risk increases with chronic alcohol use. Caffeine may exacerbate anxiety or insomnia. Monitor for signs of dependence or withdrawal. Avoid in patients with porphyria or severe hepatic impairment.
Take exactly as prescribed; do not increase dose or frequency.,Avoid alcohol while taking this medication.,Do not exceed 4000 mg acetaminophen per day from all sources.,This medication can be habit-forming; do not share with others.,May cause drowsiness; avoid driving or operating machinery until you know how it affects you.,Report signs of liver injury: yellowing skin/eyes, dark urine, abdominal pain.,Do not use for more than 5 days per week to avoid rebound headaches.
Take only as prescribed; do not exceed recommended dose due to risk of liver damage from acetaminophen.,Avoid alcohol while taking this medication to prevent liver toxicity.,This medication may cause drowsiness or dizziness; do not drive or operate machinery until you know how it affects you.,Do not use with other products containing acetaminophen to avoid overdose.,If you have a history of substance abuse, inform your doctor; this drug can be habit-forming.,Notify your doctor if you experience signs of liver problems (e.g., yellowing of skin/eyes, dark urine) or symptoms of withdrawal (e.g., anxiety, insomnia, tremors).,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICRAININ vs PHRENILIN FORTE, answered by our medical review team.
MICRAININ is a Barbiturate Combination Analgesic that works by MICRAININ is a combination of acetaminophen (paracetamol) and butalbital. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis and modulating pain perception via activation of descending serotonergic pathways. Butalbital is a barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and causing central nervous system depression.. PHRENILIN FORTE is a Barbiturate Combination Analgesic that works by Butalbital: barbiturate that enhances GABA-A receptor activity, causing CNS depression. Acetaminophen: analgesic and antipyretic via COX inhibition and central action. Caffeine: adenosine receptor antagonist, CNS stimulant.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICRAININ and PHRENILIN FORTE depend on the specific clinical indication. These are both Barbiturate Combination Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICRAININ is: 2 tablets orally at onset of migraine, then 1 tablet every 1-2 hours as needed, up to 4 tablets per attack, not to exceed 6 tablets per day. Each tablet contains isometheptene mucate 65 mg, dichloralphenazone 100 mg, and acetaminophen 325 mg.. The standard adult dose of PHRENILIN FORTE is: 1 capsule (butalbital 50 mg, acetaminophen 325 mg, caffeine 40 mg) orally every 4 hours as needed; maximum 6 capsules per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICRAININ and PHRENILIN FORTE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICRAININ is classified as Category C. MICRAININ is a combination of butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate; barbiturates are associated with increased risk of congenital malformations, par. PHRENILIN FORTE is classified as Category C. First trimester: Butalbital (barbiturate) associated with oral clefts, neural tube defects; acetaminophen generally safe, but high doses may cause oxidative stress. Second/third tr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.